MHPS’ T-Point 2 Enters Commercial Operation with the World’s Largest and Most Efficient 60 Hz Gas Turbine
1.7.2020 22:24:00 EEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems, Ltd. (MHPS) announced today that its T-Point 2 combined cycle power plant validation facility entered full commercial operation with an enhanced JAC gas turbine that sets the record for output and efficiency. The T-Point 2 plant was commissioned in March at Takasago Works in Hyogo Prefecture, Japan, to replace MHPS’ original T-Point plant and to continue MHPS’ approach — which is unlike any other manufacturer’s — to advance the limits of technology while minimizing risk to its customers. To do this, MHPS validates its new gas turbine technologies and digital solutions under long-term grid-connected operation for a minimum of 8,000 operating hours, which is equivalent to nearly one year of normal operation and is a key insurance industry criterion for fleet reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005896/en/
Mitsubishi Hitachi Power Systems’ T-Point 2 combined cycle power plant validation facility has entered full commercial operation with an enhanced JAC gas turbine that sets the record for output and efficiency. Shown: T-Point 2 at Takasago Works in Hyogo Prefecture, Japan. (Photo: Business Wire)
MHPS’ most advanced JAC gas turbine, designed for maximum efficiency and lower emissions, is now integrated with MHPS-TOMONI® digital solutions for verification and validation at T-Point 2. The gas turbine is entering commercial operation at record-setting combined cycle efficiency greater than 64% and a world’s first turbine inlet temperature of 1650°C. This gas turbine reduces carbon emissions by 65% versus coal-fired plants. In addition, it has the capability for conversion from natural gas to a blend of natural gas with 30% renewable hydrogen to reduce emissions further. Eventually it will be capable of running on 100% renewable hydrogen to completely eliminate carbon emissions.
The digital building blocks of the autonomous power plant being validated at T-Point 2 include an advanced Automatic Plant Startup package that is closely linked to the advanced analytics and diagnostics that continuously monitor the total plant. To validate complete remote operation, operations will be transferred from the local control room to the Takasago Remote Monitoring Center. Operations and maintenance building blocks under evaluation include an advanced array of acoustic, video, and thermographic data acquisition sensors monitored by advanced analytics that are being trained to identify pattern changes. T-Point 2 is also evaluating the first ever Netmation 4S Digital Control System to be used on an advanced class gas turbine combined cycle plant. Netmation 4S adds additional reliability, redundancy, and enhanced operator experience to the well-proven Netmation family of control systems.
“Unlike other manufacturers, MHPS demonstrates new gas turbine capabilities at our own combined cycle power plant before shipping to our customers. This enables us to provide unmatched performance, such as the 99.5% reliability of our J-Series gas turbines,” said Paul Browning, President and CEO of MHPS Americas and Chief Regional Officer for Europe, the Middle East, Africa and the Americas. “I congratulate our dedicated team of Engineers, Procurement, and Construction personnel for achieving commercial operation on schedule, on budget, and exceeding output and efficiency expectations. This project positions us years ahead of any manufacturer in putting the latest generation of 1650°C gas turbine technology into commercial operation. We are leading a Change in Power.”
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS recently announced that its name will soon change to Mitsubishi Power. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com
Follow us at
https://twitter.com/MHPS_Global, or
https://www.linkedin.com/company/mitsubishi-hitachi-power-systems/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005896/en/
Contact information
Communications Contact:
Sharon Prater
US: +1 407-688-6200
Sharon.Prater@amer.mhps.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom